Omega-3 (EPA/DHA): Clinical Dose Ranges and What the Research Describes

What omega-3 EPA and DHA are

Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are long-chain polyunsaturated fatty acids classified as omega-3s. They are found primarily in oily fish and in algae — the original marine source from which fish accumulate them. A third omega-3, alpha-linolenic acid (ALA), is found in plant sources (flaxseed, walnuts, chia seeds), but ALA conversion to EPA and DHA in the human body is inefficient — typically less than 10%.

EPA and DHA have distinct but overlapping biological roles. EPA is more strongly associated with eicosanoid synthesis and inflammatory signalling; DHA is a structural component of cell membranes, particularly in the brain and retina.

The clinical dose range

What trials have measured

The largest volume of evidence relates to triglyceride reduction. At doses of 2,000–4,000 mg/day of EPA+DHA, well-controlled trials consistently find reductions in serum triglycerides. This is the basis for prescription-strength omega-3 formulations available for hypertriglyceridaemia. The effect is dose-dependent and well-replicated.

For cardiovascular mortality and major cardiovascular events, the picture is more complex. The REDUCE-IT trial (4,000 mg/day EPA in the form of icosapentaenoic acid in individuals with elevated triglycerides on statins) found a significant reduction in cardiovascular events. However, the mineral oil placebo used has been criticised for potentially inflating apparent differences. Other large trials using more inert placebos have found smaller or null effects.

For inflammation markers (CRP, IL-6), small reductions have been found in trials at 1,000–3,000 mg/day, though effect sizes are modest and clinical significance in healthy individuals is unclear.

Cognitive outcomes — memory, depression, ADHD — have been studied with inconsistent results. The strongest signals are in populations with clinical depression (EPA-dominant formulations) and in children with documented ADHD, rather than in healthy adults.

Underdosing in commercial products

Omega-3 underdosing is among the most prevalent issues in the supplement market, driven almost entirely by label presentation:

• Total oil vs. active content: The most common error is reading the fish oil weight (e.g. 1,000 mg) as equivalent to EPA+DHA content. Standard fish oil typically contains 30% EPA+DHA by weight.
• Generic "fish oil" without EPA/DHA disclosure: Some products do not separately disclose EPA and DHA quantities, making dose verification impossible.
• Low-concentration products with multiple capsules: Achieving a meaningful EPA+DHA dose from standard-concentration fish oil often requires 3–5 capsules per day — which labels may not make obvious.

Documented safety considerations

Omega-3 supplementation is generally well tolerated. Reported adverse effects include fishy aftertaste, belching, and mild gastrointestinal discomfort, which are more common with lower-quality or less refined oils. At high doses (above 3,000 mg EPA+DHA/day), a mild anticoagulant effect has been documented — this is of relevance to individuals taking anticoagulant medication. The European Food Safety Authority considers 5,000 mg/day EPA+DHA safe for long-term use in healthy adults, though most supplementation falls well below this threshold.

How Proco Scanner evaluates it

When the Scanner reads an omega-3 product, it extracts the declared EPA and DHA quantities — not total fish oil weight — and checks the combined EPA+DHA content against the 1,000–3,000 mg/day evidence range. Products that do not separately disclose EPA and DHA are flagged as unverifiable for dose assessment.

Proco Scanner reads any supplement label and surfaces what the published research describes for each ingredient — dose, evidence quality, and known considerations. Coming to iOS. Join the waitlist for early access.